Affirmed Therapeutics (AFMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Affimed N.V. (AFMD) has been on a downward spiral lately with significant selling pressure. After declining 47.1% over the past four weeks, the stock looks well positioned for a trend reversal as it ...

Affimed N.V. (NASDAQ:AFMD) shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in non-small cell lung cancer (NSCLC). Affimed said ...

Leadership from AMCOM's Aviation Field Maintenance Directorate and Field Support Directorate traveled to Fort Bragg, N.C., in late June to meet with the 82nd Combat Aviation Brigade command team and ...

The big shareholder groups in Affimed N.V. (NASDAQ:AFMD) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable ...

Short interest in AFMD (AFMD) increased during the last reporting period, rising from 580.55K to 928.60K. This put -% of the company's publicly available shares short. Short interest in Corp ...

Shares of Affimed Inc.AFMD were up a massive 246.8% post announcement of a cancer collaboration agreement with Roche Holding's RHHBY subsidiary, Genentech, on Monday Aug 27. In fact, the stock has ...

World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients’ money after undertaking a rigorous examination of any potential stock. They are particularly ...

We expect investors to focus on Affimed N.V.’s AFMD progress with its three clinical programs on AFM24, acimtamig (AFM13) and AFM28, being studied for different cancer indications, when it reports ...